Okeiro

High-Level Overview

Okeiro is a precision medicine company developing AI-powered digital solutions and software medical devices to predict and prevent organ failure in transplant patients and those with advanced chronic diseases, such as kidney, lung, heart, and liver conditions.[1][2][4] Its core products include Apilife for smart telemonitoring and Predigraft, a physician decision-making tool based on the iBox algorithm, which calculates probabilities of transplant rejection and allograft survival; the platform also supports clinical trials by serving as a surrogate endpoint accepted by FDA and EMA.[1][2][3] Serving transplant centers, physicians, patients, and pharmaceutical companies, Okeiro addresses massive unmet needs—like 850 million people affected by kidney disease, 70% of organ transplants being kidneys, and over 250,000 patients on waiting lists—by enabling proactive care, personalized treatments, and faster drug development.[2][3] With national reimbursement in France and deployments in leading centers benefiting thousands, Okeiro raised €10 million in April 2025 to fuel European expansion (UK, Germany, Spain) and US market entry.[2][3]

Origin Story

Founded in 2018, Okeiro (formerly Cibiltech and Predict4Health) emerged from internationally renowned academic research at INSERM and AP-HP, France's top medical research institutions, in collaboration with experts in medicine, data science, and AI.[1][2][5] Key figures include Pierrick Arnal, CEO and co-founder, who leads the effort to translate scientific advances into practical tools, and Prof. Loupy, a strategic research partner whose work underpins the iBox technology published in top medical journals.[2][5] The idea stemmed from developing predictive models for post-transplant complications, starting with kidney transplants; early traction came from clinical validation, implementation in French transplant centers, and achieving national health insurance reimbursement for remote monitoring.[3][5] This evolution from research spinout to a deeptech startup with FDA/EMA-qualified tools marks pivotal moments, including the 2025 €10M raise led by investors like Alven and Forepont Capital Partners.[2][3]

Core Differentiators

Okeiro stands out in precision medicine through:

• Clinically validated iBox algorithm: A proprietary, FDA/EMA-qualified predictive model (as surrogate endpoint) that forecasts rejection years ahead, revolutionizing monitoring for kidney, lung, heart, liver transplants and chronic kidney disease (CKD); it's implemented in top French centers and used in trials to cut development time/costs.[2][3]
• Comprehensive platform features: Combines multidimensional data for precision remote monitoring (Apilife telemonitoring, Predigraft decision support), smart alerts for early complication detection, automated data centralization, and nurse-supported follow-up to optimize care and free provider time.[1][4]
• Stakeholder empowerment: Delivers actionable insights for physicians (proactive interventions), patients (health journey access and team communication), and pharma (accelerated research); bridges clinical care and innovation with regulatory acceptance and reimbursement.[3][4][5]
• Science-backed scalability: Rooted in APHP/INSERM partnerships, with expansion-ready tech targeting US/Europe; investors praise its "groundbreaking" IP akin to past successes like Cardiologs.[2][3]

Role in the Broader Tech Landscape

Okeiro rides the AI-driven precision medicine wave in transplantation and chronic diseases, where CKD is projected to rank 5th in global mortality by 2040 (affecting 15% in the US vs. 10% worldwide) and transplant waitlists grow amid organ shortages.[2][3] Timing is ideal amid rising AI adoption in healthcare post-COVID telehealth boom, regulatory nods (FDA/EMA surrogate status), and demand for proactive tools amid 850M kidney patients and high rejection rates.[2][4] Market forces like aging populations, pharma's need for faster trials, and reimbursement models favor Okeiro, which influences the ecosystem by redefining standards—national French reimbursement validates economics, while US entry could standardize global monitoring and cut therapy timelines.[3] As a deeptech leader, it humanizes tech by partnering academia/clinics/pharma, accelerating innovations for end-stage diseases.[5]

Quick Take & Future Outlook

Okeiro is poised to dominate AI precision monitoring with its €10M fueling 2025 US entry, European scaling, and new AI diagnostics for chronic diseases/transplants—potentially capturing share in a trillion-dollar kidney care market.[2][3] Trends like multimodal AI, regulatory fast-tracks for predictive endpoints, and RPM growth will propel it, evolving from French pioneer to global standard-setter, much like its iBox transforms trials today.[2][4] Investors eye CKD expansion beyond transplants, with Prof. Loupy's science ensuring defensibility; success hinges on US adoption, but validated traction signals outsized impact in postponing organ failure.[2] This positions Okeiro as a transformative force, directly advancing the mission to improve millions of lives through predictive power.[1]